세계의 주입 펌프 시장 : 제품별, 투여 모드별, 최종사용자별, 용도별, 지역별 - 예측(-2030년)

The infusion pump market is projected to grow from USD 19,863.5 million in 2025 to USD 28,345 million by 2030, at a CAGR of 7.4%. The increasing incidence of chronic diseases such as diabetes, cancer, and cardiovascular disorders necessitates the precise, controlled, and continuous delivery of pharmacological therapies, significantly propelling market growth for infusion pump technologies. Furthermore, advancements in device engineering have catalyzed the evolution of smart infusion systems equipped with wireless connectivity and dose-error reduction algorithms, thereby enhancing patient safety and improving the efficiency of drug administration. The shift towards home-based healthcare solutions, in contrast to traditional inpatient settings, is creating additional demand for these advanced delivery systems. Moreover, stringent regulatory frameworks and enhanced cybersecurity protocols surrounding infusion pumps are fostering the development of safer, more reliable systems, further reinforcing market expansion.

"By mode of administration, the intravenous mode of administration segment is projected to grow at the highest CAGR during the forecast period."

The intravenous (IV) mode of administration segment is rapidly emerging as the leading growth area in the pharmaceutical market, primarily due to its critical role in the rapid and precise delivery of medications, particularly within acute and emergency care environments. IV administration provides enhanced bioavailability, a crucial factor for therapies necessitating immediate therapeutic effects, such as during surgical procedures or acute medical situations. The rising incidence of chronic conditions, notably cancer, which often necessitates the intravenous administration of chemotherapeutic agents, further propels the expansion of this market. Additionally, advancements in technology, such as smart infusion pumps equipped with dose-error reduction systems, have significantly improved the safety and efficiency of IV drug delivery. These innovations, combined with stringent regulatory frameworks and reinforced cybersecurity measures, have led to heightened patient compliance with IV therapies. The convergence of these technological advancements, optimized delivery systems, and standardized clinical practices solidifies IV administration's position as the fastest-growing segment within the healthcare field.

"By application, the chemotherapy/oncology segment accounted for the largest market share in 2024."

The oncology/chemotherapy segment represents the predominant market share within the infusion pump industry, largely attributed to the escalating incidence of cancer globally, which necessitates ongoing drug administration for effective treatment. According to the World Health Organization (WHO), cancer accounted for 20 million new cases in 2022, with projections estimating 35 million cases by 2050. Infusion pumps are critical for the delivery of chemotherapy agents, providing precise and controlled drug administration that enhances therapeutic efficacy while minimizing toxicity. The advent of portable and implantable infusion pumps has transitioned chemotherapy into home care environments, further driving the expansion of this segment. Moreover, advancements in infusion technology, such as smart infusion pumps featuring wireless connectivity and integration with electronic medical records (EMRs), have significantly propelled market growth and facilitated better patient management.

"The Asia Pacific region is expected to witness the highest growth rate during the forecast period."

The Asia-Pacific region is emerging as the fastest-growing sector in the infusion pump market, largely due to significant demographic shifts, a rising incidence of chronic diseases, and advancements in healthcare infrastructure. Countries such as China, India, and Japan are witnessing an upsurge in chronic conditions-diabetes, cancer, and cardiovascular diseases-necessitating the implementation of continuous medication delivery systems like infusion pumps. This demand is exacerbated by the increasing geriatric population, which typically requires complex and long-term medical treatments. Moreover, regional governments are instrumental in bolstering market growth by amplifying investments in healthcare and enhancing infrastructure, thereby improving access to advanced medical technologies. Technological advancements, particularly the development of smart infusion pumps, are also playing a pivotal role in propelling market dynamics within the Asia-Pacific region. These innovations not only improve medication delivery precision but also allow for better patient monitoring and management, aligning with the evolving needs of healthcare systems in the region.

Breakdown of supply-side primary interviews: * By Company Type: Tier 1 (45%), Tier 2 (20%), and Tier 3 (35%) * By Designation: C-level Executives (35%), Directors (25%), and Other Designations (40%) * By Region: North America (40%), Europe (25%), Asia Pacific (20%), Latin America (10%), and Middle East & Africa (5%)

Breakdown of demand-side primary interviews: * By Company Type: Hospitals (38%), Home Care Settings (25%), Ambulatory Care Settings (20%), Academic & Research Institutes (12%), Oncology Centers (3%), Other End Users (2%) * By Designation: Healthcare Professionals (35%), Department Heads (27%), Procurement Heads (22%), and Other Designations (16%) * By Region: North America (40%), Europe (25%), Asia Pacific (20%), Latin America (10%), and Middle East & Africa (5%)

Research Coverage

This report studies the infusion pump market based on type, mode of administration, application, end user, and region. It also studies factors affecting market growth (drivers, restraints, opportunities, and challenges). It analyzes the market's opportunities and challenges and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to six main regions and respective countries.

Reasons to Buy the Report

The report can help established companies, and new or smaller firms understand market trends, which will help them capture a larger market share. Firms that purchase the report can utilize one or more of the five strategies mentioned below.

This report provides insights into the following points:

• Analysis of key drivers (rapid technological advancements in development of smart, connected, and automated pumps, heightened regulatory safety and cybersecurity requirements, increased shift to home care settings, rising prevalence of chronic diseases, and growing number of surgeries), restraints (increasing number of product recalls, stringent regulations for infusion pump approval, and rising adoption of refurbished and rental infusion pumps), opportunities (high growth potential in emerging economies, adoption of specialty infusion systems), and challenges (increase in medications errors and lack of wireless connectivity in hospitals) influencing the growth of infusion pump market.
• Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the infusion pump market
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of infusion procedures across regions.
• Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the infusion pump market.
• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the infusion pump market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS SEGMENTATION
  • 1.3.2 YEARS CONSIDERED
  • 1.3.3 INCLUSIONS AND EXCLUSIONS
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 MARKET STAKEHOLDERS
• 1.5 LIMITATIONS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH APPROACH
• 2.2 RESEARCH METHODOLOGY DESIGN
  • 2.2.1 SECONDARY RESEARCH
    • 2.2.1.1 Key data from secondary sources
  • 2.2.2 PRIMARY DATA
    • 2.2.2.1 Key data from primary sources
    • 2.2.2.2 Key industry insights
• 2.3 MARKET SIZE ESTIMATION
  • 2.3.1 BOTTOM-UP APPROACH
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.5 MARKET SHARE ANALYSIS
• 2.6 MARKET ASSUMPTIONS
  • 2.6.1 INFUSION PUMPS MARKET: ASSUMPTION ANALYSIS
  • 2.6.2 GROWTH RATE ASSUMPTIONS
• 2.7 RISK ASSESSMENT
• 2.8 LIMITATIONS
  • 2.8.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.8.2 SCOPE-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 INFUSION PUMPS MARKET OVERVIEW
• 4.2 ASIA PACIFIC: INFUSION PUMPS MARKET, BY APPLICATION & COUNTRY (2024)
• 4.3 INFUSION PUMPS MARKET: REGIONAL MIX
• 4.4 INFUSION PUMPS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.5 INFUSION PUMPS MARKET: EMERGING ECONOMIES VS. DEVELOPED MARKETS

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Technological innovation for development of automated pumps
    • 5.2.1.2 Stringent regulatory guidelines for safety & cybersecurity requirements
    • 5.2.1.3 Increasing demand for ambulatory infusion pumps in home care settings
    • 5.2.1.4 Expanding geriatric population and subsequent rise in chronic diseases
    • 5.2.1.5 Rising number of surgical procedures
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Product recalls
    • 5.2.2.2 Complex regulatory process for product commercialization
    • 5.2.2.3 Increasing adoption of refurbished & rental infusion pumps
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growth potential of emerging economies
    • 5.2.3.2 Increasing adoption of specialty infusion systems
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Rising incidence of medication errors and lack of wireless connectivity in hospitals
• 5.3 INDUSTRY TRENDS
  • 5.3.1 GROWING FOCUS ON SMART PUMP-EMR INTEROPERABILITY
  • 5.3.2 DEVELOPMENT OF HYBRID CLOSED-LOOP SYSTEMS/ARTIFICIAL PANCREAS DEVICE SYSTEMS
  • 5.3.3 INCREASING DEMAND FOR SPECIALTY PUMPS AND ADVANCED FEATURES
• 5.4 TECHNOLOGY ANALYSIS
  • 5.4.1 KEY TECHNOLOGIES
    • 5.4.1.1 Flow generation
    • 5.4.1.2 Smart infusion systems
    • 5.4.1.3 Closed-loop infusion control systems
  • 5.4.2 COMPLEMENTARY TECHNOLOGIES
    • 5.4.2.1 Dose-error reduction systems
    • 5.4.2.2 Wireless connectivity
    • 5.4.2.3 AI-powered decision support systems
  • 5.4.3 ADJACENT TECHNOLOGIES
    • 5.4.3.1 Embedded software
    • 5.4.3.2 Sensing technology
    • 5.4.3.3 Telemedicine platforms
• 5.5 PORTER'S FIVE FORCES ANALYSIS
  • 5.5.1 THREAT OF NEW ENTRANTS
  • 5.5.2 THREAT OF SUBSTITUTES
  • 5.5.3 BARGAINING POWER OF SUPPLIERS
  • 5.5.4 BARGAINING POWER OF BUYERS
  • 5.5.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.6 REGULATORY LANDSCAPE
  • 5.6.1 REGULATORY ANALYSIS
  • 5.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.7 PATENT ANALYSIS
  • 5.7.1 PATENT PUBLICATION TRENDS FOR INFUSION PUMPS
  • 5.7.2 INSIGHTS: JURISDICTION & TOP APPLICANT ANALYSIS
• 5.8 TRADE ANALYSIS
  • 5.8.1 TRADE DATA FOR HS CODE 901890
    • 5.8.1.1 Import data for HS Code 901890
    • 5.8.1.2 Export data for HS Code 901890
• 5.9 PRICING ANALYSIS
  • 5.9.1 AVERAGE SELLING PRICE, BY KEY PLAYER
    • 5.9.1.1 Average selling price trend of key players, by device
  • 5.9.2 AVERAGE SELLING PRICE, BY REGION
    • 5.9.2.1 Average selling price of volumetric infusion pumps, insulin pumps, and syringe infusion pumps, by region, 2024
    • 5.9.2.2 Average selling price trend of volumetric infusion pumps, by region, 2022-2024
    • 5.9.2.3 Average selling price trend of insulin pumps, by region, 2022-2024
    • 5.9.2.4 Average selling price trend of ambulatory infusion pumps, by region, 2022-2024
    • 5.9.2.5 Average selling price trend of syringe infusion pumps, by region, 2022-2024
    • 5.9.2.6 Average selling price trend of enteral infusion pumps, by region
    • 5.9.2.7 Average selling price trend of PCA pumps, by region, 2022-2024
    • 5.9.2.8 Average selling price trend of implantable infusion pumps, by region, 2022-2024
• 5.10 REIMBURSEMENT ANALYSIS
• 5.11 KEY CONFERENCES & EVENTS, 2025-2026
• 5.12 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.12.2 BUYING CRITERIA
• 5.13 UNMET NEEDS/END-USER EXPECTATIONS
• 5.14 IMPACT OF AI/GENERATIVE AI ON INFUSION PUMPS MARKET
  • 5.14.1 INTRODUCTION
  • 5.14.2 MARKET POTENTIAL OF INFUSION PUMPS ECOSYSTEM
  • 5.14.3 AI USE CASES
  • 5.14.4 KEY COMPANIES IMPLEMENTING AI IN INFUSION PUMPS
  • 5.14.5 FUTURE OF GEN AI ACROSS INFUSION PUMPS ECOSYSTEM
• 5.15 ECOSYSTEM MARKET MAP
• 5.16 CASE STUDY ANALYSIS
  • 5.16.1 RELIABILITY ANALYSIS OF HOSPITAL INFUSION PUMPS
  • 5.16.2 NEXT GENERATION MEDICAL INFUSION PUMP
  • 5.16.3 ENHANCEMENT OF MEDICATION DELIVERY WITH INTEROPERABILITY FEATURES OF SMART INFUSION PUMPS
• 5.17 SUPPLY/VALUE CHAIN ANALYSIS
• 5.18 ADJACENT MARKET ANALYSIS
• 5.19 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.20 INVESTMENT & FUNDING SCENARIO
• 5.21 TRUMP TARIFF IMPACT ON INFUSION PUMPS MARKET
  • 5.21.1 INTRODUCTION
  • 5.21.2 KEY TARIFF RATES
  • 5.21.3 PRICE IMPACT ANALYSIS
  • 5.21.4 IMPACT ON COUNTRY/REGION
  • 5.21.5 END-USE INDUSTRY IMPACT

6 INFUSION PUMPS MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 ACCESSORIES AND CONSUMABLES
  • 6.2.1 DEDICATED ACCESSORIES AND CONSUMABLES
    • 6.2.1.1 Volumetric infusion pump dedicated disposables
      • 6.2.1.1.1 Growing installation for deliverance of medication & nutrients to boost demand
    • 6.2.1.2 Insulin pump dedicated disposables
      • 6.2.1.2.1 Rising number of insulin-dependent diabetic patients to support market growth
    • 6.2.1.3 Enteral infusion pump dedicated disposables
      • 6.2.1.3.1 Ability to provide precision & consistency in results to fuel market
    • 6.2.1.4 Syringe infusion pump dedicated disposables
      • 6.2.1.4.1 High demand in emerging economies to drive market
    • 6.2.1.5 Ambulatory infusion pump dedicated disposables
      • 6.2.1.5.1 Growing preference for home care settings to boost demand
    • 6.2.1.6 PCA pump dedicated disposables
      • 6.2.1.6.1 Growing focus on critical pain management to boost market
    • 6.2.1.7 Implantable infusion pump dedicated disposables
      • 6.2.1.7.1 Compatibility features to aid adoption
  • 6.2.2 NON-DEDICATED ACCESSORIES AND CONSUMABLES
    • 6.2.2.1 Infusion catheters
      • 6.2.2.1.1 Potential for recurrent use to drive demand
    • 6.2.2.2 IV administration sets
      • 6.2.2.2.1 Rising demand across various systems to propel market
    • 6.2.2.3 Needleless connectors
      • 6.2.2.3.1 Reduction in bloodstream infection risks to drive demand
    • 6.2.2.4 Cannulas
      • 6.2.2.4.1 Ability to ease patient discomfort to boost demand
    • 6.2.2.5 Tubing and extension sets
      • 6.2.2.5.1 Need for continuous and efficient connections to drive market
    • 6.2.2.6 Valves
      • 6.2.2.6.1 Improvement in infusion quality to drive market
    • 6.2.2.7 Other non-dedicated accessories and consumables
• 6.3 DEVICES
  • 6.3.1 DEVICES MARKET, BY TYPE
    • 6.3.1.1 Volumetric infusion pumps
      • 6.3.1.1.1 Technological improvements to boost market
    • 6.3.1.2 Insulin pumps
      • 6.3.1.2.1 High demand for diabetes to propel market
    • 6.3.1.3 Ambulatory infusion pumps
      • 6.3.1.3.1 Disposable infusion pumps
        • 6.3.1.3.1.1 Portability & ease of operation to fuel demand
      • 6.3.1.3.2 Chemotherapy infusion pumps
        • 6.3.1.3.2.1 Growing focus on injecting oncology drugs in home care settings to fuel uptake
    • 6.3.1.4 Syringe infusion pumps
      • 6.3.1.4.1 Cost-effectiveness and portability to drive market
    • 6.3.1.5 Enteral infusion pumps
      • 6.3.1.5.1 Technological advancements to bolster market
    • 6.3.1.6 PCA pumps
      • 6.3.1.6.1 Pre-programmed delivery of fixed number of analgesics to fuel adoption
    • 6.3.1.7 Implantable infusion pumps
      • 6.3.1.7.1 Growing use for long-term delivery of opioid medication to drive market
  • 6.3.2 DEVICES MARKET, BY TECHNOLOGY
    • 6.3.2.1 Traditional infusion pumps
      • 6.3.2.1.1 Utilization across long-term care settings to drive market
    • 6.3.2.2 Specialty infusion pumps
      • 6.3.2.2.1 Lightweight mobility to fuel uptake
  • 6.3.3 DEVICES MARKET, BY MODE
    • 6.3.3.1 Stationary infusion pumps
      • 6.3.3.1.1 Ability to deliver medication through multiple routes to support market uptake
    • 6.3.3.2 Portable infusion pumps
      • 6.3.3.2.1 Convenience and remote availability to boost demand

7 INFUSION PUMPS MARKET, BY MODE OF ADMINISTRATION

• 7.1 INTRODUCTION
• 7.2 INTRAVENOUS (IV)
  • 7.2.1 RAPID AND CONTROLLED DIRECT DELIVERY TO PROPEL MARKET
• 7.3 SUBCUTANEOUS
  • 7.3.1 ADMINISTRATION OF MEDICATIONS INTO TISSUE LAYERS FOR SLOW & SUSTAINED RELEASE TO FUEL UPTAKE
• 7.4 EPIDURAL
  • 7.4.1 ANALGESIC/ANESTHETIC AGENT TRANSMISSION FOR TARGETED PAIN RELIEF TO DRIVE MARKET
• 7.5 ENTERAL
  • 7.5.1 ADOPTION OF PORTABLE & SMART ENTERAL INFUSION SYSTEMS TO SUPPORT MARKET GROWTH
• 7.6 INTRATHECAL
  • 7.6.1 MEDICATION DELIVERY FOR CHRONIC PAIN RELIEF & MANAGEMENT TO FUEL UPTAKE

8 INFUSION PUMPS MARKET, BY END USER

• 8.1 INTRODUCTION
• 8.2 HOSPITALS
  • 8.2.1 HIGH PURCHASING POWER FOR TECHNOLOGICALLY ADVANCED INFUSION DEVICES TO DRIVE MARKET
• 8.3 HOME CARE SETTINGS
  • 8.3.1 DEVELOPMENT OF COMPACT & PORTABLE DEVICES TO BOOST DEMAND
• 8.4 AMBULATORY CARE SETTINGS
  • 8.4.1 GROWING AVAILABILITY ACROSS CRITICAL CARE SETTINGS TO DRIVE MARKET
• 8.5 ACADEMIC & RESEARCH INSTITUTES
  • 8.5.1 INCREASING FOCUS ON R&D ACTIVITIES FOR THERAPEUTIC CLINCIAL TRIALS TO AID MARKET
• 8.6 ONCOLOGY CENTERS
  • 8.6.1 INCREASING REQUIREMENT FOR PRECISE & CONTROLLED DELIVERY OF CHEOMOTHERAPIC AGENTS TO SUPPORT MARKET GROWTH
• 8.7 OTHER END USERS

9 INFUSION PUMPS MARKET, BY APPLICATION

• 9.1 INTRODUCTION
• 9.2 CHEMOTHERAPY/ONCOLOGY
  • 9.2.1 HIGH INCIDENCE OF CANCER AND GROWING DEVELOPMENT OF ONCOLOGY THERAPEUTICS TO DRIVE MARKET
• 9.3 DIABETES MANAGEMENT
  • 9.3.1 INCREASING FOCUS ON SUSTAINED MEDICATION DELIVERY TO BOOST DEMAND
• 9.4 GASTROENTEROLOGY
  • 9.4.1 INCREASING PREVALENCE OF IBD AND GASTROINTESTINAL INFECTIONS TO FUEL UPTAKE
• 9.5 ANALGESIA/PAIN MANAGEMENT
  • 9.5.1 RISING NUMBER OF SURGICAL PROCEDURES TO PROPEL MARKET
• 9.6 PEDIATRICS/NEONATOLOGY
  • 9.6.1 INCREASING INCIDENCE OF PEDIATRIC DIABETES TO SUPPORT MARKET GROWTH
• 9.7 HEMATOLOGY
  • 9.7.1 INCREASING PREVALENCE OF ANEMIA AND BLOOD DISORDERS TO FUEL UPTAKE
• 9.8 OTHER APPLICATIONS

10 INFUSION PUMPS MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 10.2.2 US
    • 10.2.2.1 Expansion in home care settings to fuel market
  • 10.2.3 CANADA
    • 10.2.3.1 Increasing incidence of chronic diseases to drive market
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 10.3.2 GERMANY
    • 10.3.2.1 Presence of leading infusion pump manufacturers to drive market
  • 10.3.3 FRANCE
    • 10.3.3.1 Well-established healthcare system to support market growth
  • 10.3.4 UK
    • 10.3.4.1 NHS Digital Strategy and Homecare Shift Accelerate Infusion Pump Adoption in the UK
  • 10.3.5 SPAIN
    • 10.3.5.1 Rising prevalence of cancer to drive demand
  • 10.3.6 ITALY
    • 10.3.6.1 Growing demand for cost-effective home care to drive market
  • 10.3.7 NETHERLANDS
    • 10.3.7.1 Strong healthcare infrastructure and aging population to drive market
  • 10.3.8 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 10.4.2 CHINA
    • 10.4.2.1 Growing investments in healthcare infrastructure to drive market
  • 10.4.3 JAPAN
    • 10.4.3.1 Large geriatric population to drive demand
  • 10.4.4 INDIA
    • 10.4.4.1 Increasing demand for advanced medical treatment to boost market
  • 10.4.5 THAILAND
    • 10.4.5.1 Medical tourism to drive demand
  • 10.4.6 VIETNAM
    • 10.4.6.1 Rising prevalence of chronic conditions to boost demand
  • 10.4.7 AUSTRALIA
    • 10.4.7.1 Increasing incidence of cancer & diabetes to fuel uptake
  • 10.4.8 SOUTH KOREA
    • 10.4.8.1 Integration of smart technologies to boost demand
  • 10.4.9 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 10.5.2 BRAZIL
    • 10.5.2.1 Rising healthcare expenditure to drive market
  • 10.5.3 MEXICO
    • 10.5.3.1 Growth in medical devices industry to fuel market
  • 10.5.4 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 10.6.2 GCC COUNTRIES
    • 10.6.2.1 Kingdom of Saudi Arabia (KSA)
      • 10.6.2.1.1 Significant healthcare investments to fuel uptake
    • 10.6.2.2 United Arab Emirates (UAE)
      • 10.6.2.2.1 Integration of EMR into smart pumps to fuel adoption
    • 10.6.2.3 Other GCC Countries
  • 10.6.3 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

• 11.1 OVERVIEW
• 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN INFUSION PUMPS MARKET
• 11.3 REVENUE ANALYSIS, 2020-2024
• 11.4 MARKET SHARE ANALYSIS, 2024
  • 11.4.1 VOLUMETRIC INFUSION PUMPS MARKET
  • 11.4.2 SYRINGE INFUSION PUMPS MARKET
  • 11.4.3 INSULIN PUMPS MARKET
  • 11.4.4 ENTERAL INFUSION PUMPS MARKET
  • 11.4.5 US: INFUSION PUMPS MARKET SHARE ANALYSIS
  • 11.4.6 EUROPE: INFUSION PUMPS MARKET SHARE ANALYSIS
  • 11.4.7 US: INSULIN PUMPS MARKET SHARE ANALYSIS
  • 11.4.8 RANKING OF KEY MARKET PLAYERS
• 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 11.5.1 STARS
  • 11.5.2 EMERGING LEADERS
  • 11.5.3 PERVASIVE PLAYERS
  • 11.5.4 PARTICIPANTS
  • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 11.5.5.1 Company footprint
    • 11.5.5.2 Region footprint
    • 11.5.5.3 Product footprint
    • 11.5.5.4 Mode of administration footprint
    • 11.5.5.5 Application footprint
• 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 11.6.1 PROGRESSIVE COMPANIES
  • 11.6.2 DYNAMIC COMPANIES
  • 11.6.3 STARTING BLOCKS
  • 11.6.4 RESPONSIVE COMPANIES
  • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 11.6.5.1 Detailed list of key startups/SME players
    • 11.6.5.2 Competitive benchmarking of key emerging players/startups
• 11.7 BRAND/PRODUCT COMPARATIVE ANALYSIS
• 11.8 R&D EXPENDITURE OF KEY PLAYERS
• 11.9 COMPANY VALUATION & FINANCIAL METRICS
  • 11.9.1 FINANCIAL METRICS
  • 11.9.2 COMPANY VALUATION
• 11.10 COMPETITIVE SCENARIO
  • 11.10.1 PRODUCT LAUNCHES & APPROVALS
  • 11.10.2 DEALS
  • 11.10.3 EXPANSIONS
  • 11.10.4 OTHER DEVELOPMENTS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 BECTON, DICKINSON AND COMPANY
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Product approvals
      • 12.1.1.3.2 Deals
      • 12.1.1.3.3 Expansions
      • 12.1.1.3.4 Other developments
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Key strengths
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses & competitive threats
  • 12.1.2 BAXTER INTERNATIONAL, INC.
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Product launches
      • 12.1.2.3.2 Deals
      • 12.1.2.3.3 Other developments
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Key strengths
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses & competitive threats
  • 12.1.3 B. BRAUN SE
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Product launches & approvals
      • 12.1.3.3.2 Deals
      • 12.1.3.3.3 Other developments
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Key strengths
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses & competitive threats
  • 12.1.4 MEDTRONIC
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Product launches & approvals
      • 12.1.4.3.2 Deals
    • 12.1.4.4 MnM view
      • 12.1.4.4.1 Key strengths
      • 12.1.4.4.2 Strategic choices
      • 12.1.4.4.3 Weaknesses & competitive threats
  • 12.1.5 FRESENIUS KABI AG
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Product approvals
      • 12.1.5.3.2 Deals
      • 12.1.5.3.3 Other developments
    • 12.1.5.4 MnM view
      • 12.1.5.4.1 Key strengths
      • 12.1.5.4.2 Strategic choices
      • 12.1.5.4.3 Weaknesses & competitive threats
  • 12.1.6 ICU MEDICAL, INC.
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products offered
    • 12.1.6.3 Recent developments
      • 12.1.6.3.1 Product launches & approvals
      • 12.1.6.3.2 Deals
      • 12.1.6.3.3 Other developments
  • 12.1.7 TERUMO CORPORATION
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products offered
    • 12.1.7.3 Recent developments
      • 12.1.7.3.1 Product launches
      • 12.1.7.3.2 Expansions
      • 12.1.7.3.3 Deals
  • 12.1.8 NIPRO
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products offered
    • 12.1.8.3 Recent developments
      • 12.1.8.3.1 Expansions
  • 12.1.9 AVANOS MEDICAL, INC.
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products offered
  • 12.1.10 INSULET CORPORATION
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products offered
    • 12.1.10.3 Recent developments
      • 12.1.10.3.1 Product launches & approvals
      • 12.1.10.3.2 Deals
      • 12.1.10.3.3 Expansions
  • 12.1.11 TANDEM DIABETES CARE, INC.
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products offered
    • 12.1.11.3 Recent developments
      • 12.1.11.3.1 Product launches & approvals
      • 12.1.11.3.2 Deals
  • 12.1.12 JMS CO., LTD.
    • 12.1.12.1 Business overview
    • 12.1.12.2 Products offered
  • 12.1.13 F. HOFFMANN-LA ROCHE LTD.
    • 12.1.13.1 Business overview
    • 12.1.13.2 Products offered
    • 12.1.13.3 Recent developments
      • 12.1.13.3.1 Other developments
  • 12.1.14 MOOG, INC.
    • 12.1.14.1 Business overview
    • 12.1.14.2 Products offered
      • 12.1.14.2.1 Product launches & enhancements
      • 12.1.14.2.2 Other developments
  • 12.1.15 TELEFLEX INCORPORATED
    • 12.1.15.1 Business overview
    • 12.1.15.2 Products offered
  • 12.1.16 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
    • 12.1.16.1 Business overview
    • 12.1.16.2 Products offered
    • 12.1.16.3 Recent developments
      • 12.1.16.3.1 Product launches
  • 12.1.17 YPSOMED
    • 12.1.17.1 Business overview
    • 12.1.17.2 Products offered
    • 12.1.17.3 Recent developments
      • 12.1.17.3.1 Product launches & enhancements
      • 12.1.17.3.2 Deals
      • 12.1.17.3.3 Expansions
  • 12.1.18 POLYMEDICURE
    • 12.1.18.1 Business overview
    • 12.1.18.2 Products offered
  • 12.1.19 ROMSONS.IN
    • 12.1.19.1 Business overview
    • 12.1.19.2 Products offered
  • 12.1.20 PROMED TECHNOLOGY CO., LIMITED
    • 12.1.20.1 Business overview
    • 12.1.20.2 Products offered
  • 12.1.21 MEDCAPTAIN MEDICAL TECHNOLOGY CO., LTD.
    • 12.1.21.1 Business overview
    • 12.1.21.2 Products offered
• 12.2 OTHER PLAYERS
  • 12.2.1 MICREL MEDICAL DEVICES SA
  • 12.2.2 INTUVIE HOLDINGS LLC
  • 12.2.3 EPIC MEDICAL
  • 12.2.4 SOOIL DEVELOPMENTS CO., LTD.
  • 12.2.5 SHENZHEN MEDRENA BIOTECH CO., LTD
  • 12.2.6 CODAN COMPANIES
  • 12.2.7 EITAN MEDICAL
  • 12.2.8 ANGIPLAST PRIVATE LIMITED
  • 12.2.9 BEIJING KELLYMED CO.

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 RELATED REPORTS
• 13.4 AUTHOR DETAILS